Search Results - "Lymp, J"

Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection by Clancy, J P, Dupont, L, Konstan, M W, Billings, J, Fustik, S, Goss, C H, Lymp, J, Minic, P, Quittner, A L, Rubenstein, R C, Young, K R, Saiman, L, Burns, J L, Govan, J R W, Ramsey, B, Gupta, R

“…Arikace is a liposomal amikacin preparation for aerosol delivery with potent Pseudomonas aeruginosa killing and prolonged lung deposition. To examine the…”
Get more information

Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial by Conrad, C, Lymp, J, Thompson, V, Dunn, C, Davies, Z, Chatfield, B, Nichols, D, Clancy, J, Vender, R, Egan, M.E, Quittell, L, Michelson, P, Antony, V, Spahr, J, Rubenstein, R.C, Moss, R.B, Herzenberg, L.A, Goss, C.H, Tirouvanziam, R

“…Abstract Purpose To evaluate the effects of oral N-acetylcysteine (NAC), which replenishes systemic glutathione, on decreasing inflammation and improving lung…”
Get full text

TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) by Morschhauser, F., Dahiya, S., Palomba, M. L., Garcia‐Sancho, A. M., Ortega, J. L. Reguera, Kuruvilla, J., Jager, U., Cartron, G., Izutsu, K., Dreyling, M., Kahl, B., Ghesquieres, H., Ardeshna, K., Goto, H., Barbui, A. M., Abramson, J. S., Borchmann, P., Fleury, I., Mielke, S., Farazi, T., Fasan, O., Lymp, J., Vedal, M., Nishii, R., Avilion, A., Papuga, J., Nastoupil, L. J.

Get full text

OUTREACH: PRELIMINARY SAFETY & EFFICACY RESULTS FROM A PHASE 2 STUDY OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN THE NONUNIVERSITY SETTING by Godwin, J. E., Mattar, B., Maris, M., Bachier, C., Stevens, D. A., Hoda, D., Varela, J. C., Cherry, M., Fanning, S., Essell, J., Yimer, H., Courtright, J., Sharman, J., Trede, N. S., Youssef, M., Lymp, J., Shaughnessy, P.

Get full text

TREATMENT OF RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMA (NHL) WITH LISOCABTAGENE MARALEUCEL IN THE OUTPATIENT SETTING: RESULTS FROM TWO PHASE 2 TRIALS by Sehgal, A., Godwin, J.E., Maris, M.B., Hildebrandt, G.C., Trede, N.S., Kostic, A., Wang, L., Lymp, J., Bachier, C.R.

Get full text

Durable responses after CD19‐targeted CAR‐T cell immunotherapy with concurrent ibrutinib for CLL after prior ibrutinib failure by Gauthier, J., Hirayama, A.V., Hay, K.A., Lymp, J., Li, D., Sheih, A., Purushe, J., Pender, B.S., Hawkins, R.M., Vakil, A., Phi, T., Steinmetz, R.N., Riddell, S.R., Maloney, D.G., Turtle, C.J.

Get full text

Validation of parent self reported home safety practices by Robertson, A S, Rivara, F P, Ebel, B E, Lymp, J F, Christakis, D A

“…Objectives: To evaluate the validity of parents’ self reported home safety practices concerning smoke detectors, bike helmets, car seats, and water heater…”
Get full text

Survey assessment of personal digital assistant use among trainees and attending physicians by McLeod, Thomas G, Ebbert, Jon O, Lymp, James F

“…Limited information is available on personal digital assistant (PDA) use patterns in medical settings. Recognizing that use patterns may be important…”
Get full text

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study by Morschhauser, Franck, Dahiya, Saurabh, Palomba, M. Lia, Martin Garcia-Sancho, Alejandro, Reguera Ortega, Juan Luis, Kuruvilla, John, Jäger, Ulrich, Cartron, Guillaume, Izutsu, Koji, Dreyling, Martin, Kahl, Brad, Ghesquieres, Hervé, Ardeshna, Kirit, Goto, Hideki, Barbui, Anna Maria, Abramson, Jeremy S., Borchmann, Peter, Fleury, Isabelle, Mielke, Stephan, Skarbnik, Alan, de Vos, Sven, Kamdar, Manali, Karmali, Reem, Viardot, Andreas, Farazi, Thalia, Fasan, Omotayo, Lymp, James, Vedal, Min, Nishii, Rina, Avilion, Ariel, Papuga, Jessica, Kumar, Jinender, Nastoupil, Loretta J.

“…An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of disease within…”
Get full text

Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study by Morschhauser, Franck, Dahiya, Saurabh, Palomba, M. Lia, Martin Garcia-Sancho, Alejandro, Reguera Ortega, Juan Luis, Kuruvilla, John, Jäger, Ulrich, Cartron, Guillaume, Izutsu, Koji, Dreyling, Martin, Kahl, Brad, Ghesquieres, Hervé, Ardeshna, Kirit, Goto, Hideki, Barbui, Anna Maria, Abramson, Jeremy S., Borchmann, Peter, Fleury, Isabelle, Mielke, Stephan, Skarbnik, Alan, de Vos, Sven, Kamdar, Manali, Karmali, Reem, Viardot, Andreas, Farazi, Thalia, Fasan, Omotayo, Lymp, James, Vedal, Min, Nishii, Rina, Avilion, Ariel, Papuga, Jessica, Kumar, Jinender, Nastoupil, Loretta J.

Get full text

Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease by Suzuki, Ayako, Lindor, Keith, Saver, Jenny St, Lymp, James, Mendes, Flavia, Muto, Ayako, Okada, Toshihide, Angulo, Paul

“…The effects of lifestyle modifications in nonalcoholic fatty liver disease (NAFLD) are incompletely defined. We aimed at determining the association of changes…”
Get full text

The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis by LEVY, Cynthia, LYMP, James, ANGULO, Paul, GORES, Gregory J, LARUSSO, Nicholas, LINDOR, Keith D

“…CA 19-9 has been used with questionable accuracy to aid diagnosis of cholangiocarcinoma complicating primary sclerosing cholangitis. We aimed to characterize…”
Get full text

Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease by Suzuki, Ayako, Angulo, Paul, Lymp, James, Li, Dave, Satomura, Shinji, Lindor, Keith

“…: Aim: To determine whether serum hyaluronic acid reliably predicts the severity of hepatic fibrosis in patients with non‐alcoholic fatty liver disease…”
Get full text

Chronological development of elevated aminotransferases in a nonalcoholic population by SUZUKI, Ayako, ANGULO, Paul, LYMP, James, SAUVER, Jennifer St, MUTO, Ayako, OKADA, Toshihide, LINDOR, Keith

“…The incidence and risk factors of nonalcoholic fatty liver disease (NAFLD) have never been prospectively determined. To determine the frequency and risk…”
Get full text

TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL) by Nastoupil, LJ, Dahiya, S, Palomba, ML, Garcia-Sancho, AM, Ortega, JLR, Kuruvilla, J, Jager, U, Cartron, G, Izutsu, KI, Dreyling, M, Kahl, B, Ghesquieres, H, Ardeshna, K, Goto, H, Barbui, AM, Abramson, JS, Borchmann, P, Fleury, I, Mielke, S, Farazi, T, Fasan, O, Lymp, J, Vedal, M, Nishii, R, Avilion, A, Papuga, J, Morschhauser, F

Get full text

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as SecondLine Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma by Morschhauser, F, Dahiya, S, Palomba, ML, Garcia-Sancho, AM, Reguera, JL, Kuruvilla, J, Jaeger, U, Cartron, G, Izutsu, K, Dreyling, M, Kahl, BS, Ghesquieres, H, Ardeshna, K, Goto, H, Barbui, AM, Abramson, JS, Borchmann, P, Fleury, I, Mielke, S, Skarbnik, A, de Vos, S, Kamdar, M, Karmali, R, Viardot, A, Farazi, T, Fasan, O, Lymp, J, Vedal, M, Nishii, R, Avilion, A, Papuga, J, Nastoupil, LJ

Get full text

Improved Specificity of Newborn Screening for Congenital Adrenal Hyperplasia by Second-Tier Steroid Profiling Using Tandem Mass Spectrometry by Lacey, Jean M, Minutti, Carla Z, Magera, Mark J, Tauscher, Angela L, Casetta, Bruno, McCann, Mark, Lymp, James, Hahn, Si Houn, Rinaldo, Piero, Matern, Dietrich

“…Newborn screening for congenital adrenal hyperplasia (CAH) involves measurement of 17alpha-hydroxyprogesterone (17-OHP), usually by immunoassay. Because this…”
Get full text

Hazardous materials events: Evaluation of transport to health care facility and evacuation decisions by Burgess, Jefferey L., Kovalchick, Dana F., Harter, Lucy, Kyes, Kelly B., Lymp, James F., Brodkin, Carl A.

“…The study objective was to analyze hazardous materials event and victim factors associated with transportation of victims to a health care facility, and…”
Get full text

Risk Factors for Adverse Health Effects Following Hazardous Materials Incidents by Burgess, Jefferey L., Kovalchick, Dana F., Lymp, James F., Kyes, Kelly B., Robertson, William O., Brodkin, Carl A.

“…To identify risk factors for persistent morbidity, we conducted a prospective study of individuals involved in hazardous materials incidents reported to the…”
Get full text

The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study by Adams, Leon A., Lymp, James F., St. Sauver, Jenny, Sanderson, Schuyler O., Lindor, Keith D., Feldstein, Ariel, Angulo, Paul

“…Background & Aims: The natural history of nonalcoholic fatty liver disease (NAFLD) in the community remains unknown. We sought to determine survival and…”
Get full text